Species-specific surrogate apoB ASOs in mouse, hamster, rabbit and monkey lipid models (mouse atherosclerosis models)
“Nonclinical pharmacology studies with these apoB antisense inhibitors have shown rapid reduction of hepatic apoB mRNA and protein, and reductions in serum apoB, LDL-C and total-C in mouse, hamster, rabbit and monkey models.”
✓ VerifiedFDA pharmacology/toxicology review, p. 19Source ↗
Why that model
apoB mRNA sequence differences reduce (monkey) or abolish (mouse, rat, dog, rabbit) mipomersen activity
“Species-specific differences in the nucleotide sequence of apoB mRNA caused a reduction (monkey) or complete loss (mouse, rat, dog and rabbit) of the intended pharmacological activity of mipomersen in these species.”
✓ VerifiedFDA pharmacology/toxicology review, p. 19Source ↗
Reviewer's view of the efficacy data
FDA: surrogate studies provide proof-of-concept for targeting apoB100 with antisense
“These studies provide proof-of-concept support for the utility of targeting apoB100 using antisense molecules.”
✓ VerifiedFDA pharmacology/toxicology review, p. 19Source ↗